Development of breeding populations of rhesus macaques (Macaca mulatta) that are specific pathogen-free for rhesus cytomegalovirus

Comparative Medicine

Volumn 58, Issue 1, 2008, Pages 43-46

  Barry, Peter A ^a,b,c   Strelow, Lisa ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREEDING; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE TRANSMISSION; GERMFREE ANIMAL; HUMAN CYTOMEGALOVIRUS; MACACA; NONHUMAN; REVIEW; RHESUS CYTOMEGALOVIRUS; RHESUS MONKEY; SEROLOGY; SEROPREVALENCE;

ANIMALS; BREEDING; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; FEMALE; FETAL DISEASES; HOUSING, ANIMAL; HUMANS; MACACA MULATTA; MALE; MICE; PREGNANCY; SALIVA; SPECIFIC PATHOGEN-FREE ORGANISMS; VIRUS ACTIVATION;

EID: 40949111057     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Asher DM, Gibbs CJ Jr, Lang DJ, Gadjusek DC, Chanock RM. 1974. Persistent shedding of cytomegalovirus in the urine of healthy rhesus monkeys. Proc Soc Exp Biol Med 145:794-801.
2. Barry PA, Chang W-LW. 2007. Primate betaherpesviruses. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, editors. Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge (UK): Cambridge University Press.
3. Britt W. 2006. Human cytomegalovirus infections and mechanisms of disease. In: Reddehase MJ, editor. Cytomegaloviruses: molecular biology and immunology. Wymondham (UK): Caister Academic Press.
4. Danesh J, Collins R, Peto R. 1997. Chronic infections and coronary heart disease: is there a link? Lancet 350:430-436.
5. Hansen SG, Strelow LI, Franchi DC, Anders DG, Wong SW. 2003. Complete sequence and genomic analysis of rhesus cytomegalovirus. J Virol 77:6620-6636.
6. Huff JL, Barry PA. 2003. B-virus (Cercopithecine herpesvirus 1) infection in humans and macaques: potential for zoonotic disease. Emerg Infect Dis 9:246-250.
7. Huff JL, Eberle R, Capitanio J, Zhou S-S, Barry PA. 2003. Differential detection of B virus and rhesus cytomegalovirus in rhesus macaques. J Gen Virol 84:83-92.
8. Jones-Engel L, Engel GA, Heidrich J, Chalise M, Poudel N, Viscidi R, Barry PA, Allan JS, Grant R, Kyes R. 2006. Temple monkeys and health implications of commensalism, Kathmandu, Nepal. Emerg Infect Dis 12:900-906.
9. Khanna R, Diamond DJ. 2006. Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol Med 12:26-33.
10. Koch S, Larbi A, Ozcelik D, Solana R, Gouttefangeas C, Attig S, Wikby A, Strindhall J, Franceschi C, Pawelec G. 2007. Cytomegalovirus infection: a driving force in human T cell immunosenescence. Ann N Y Acad Sci 1114:23-35.
11. Liu R, Moroi M, Yamamoto M, Kubota T, Ono T, Funatsu A, Komatsu H, Tsuji T, Hara H, Hara H, Nakamura M, Hirai H, Yamaguchi T. 2006. Presence and severity of Chlamydia pneumoniae and Cytomegalovirus infection in coronary plaques are associated with acute coronary syndromes. Int Heart J 47:511-519.
12. Lockridge KM, Sequar G, Zhou SS, Yue Y, Mandell CP, Barry PA. 1999. Pathogenesis of experimental rhesus cytomegalovirus infection. J Virol 73:9576-9583.
13. Ludewig B, Krebs P, Scandella E. 2004. Immunopathogenesis of atherosclerosis. J Leuk Biol 76:300-306.
14. Oxford KL, Eberhardt MK, Yang K-W, Strelow L, Kelly S, Zhou S-S, Barry PA. 2008. Protein coding content of the ULb′ region of wild-type rhesus cytomegalovirus. J Genl Virol Forthcoming.
15. Rivailler P, Kaur A, Johnson RP, Wang F. 2006. Genomic sequence of rhesus cytomegalovirus 180.92: insights into the coding potential of rhesus cytomegalovirus. J Virol 80:4179-4182.
16. Stratton KR, Durch JS, Lawrence RS. 2000. Vaccines for the 21st century: a tool for decisionmaking. Washington (DC): National Academy Press. p 16-172.
17. Streblow DN, Kreklywich CN, Smith P, Soule JL, Meyer C, Yin M, Beisser P, Vink C, Nelson JA, Orloff SL. 2005. Rat cytomegalovirus-accelerated transplant vascular sclerosis is reduced with mutation of the chemokine receptor R33. Am J Transplant 5:436-442.
18. Streblow DN, Soderberg-Naucler C, Vieira J, Smith P, Wakabayashi E, Ruchti F, Mattison K, Altschuler Y, Nelson JA. 1999. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell 99:511-520.
19. Valentine HA. 2004. The role of viruses in cardiac allograft vasculopathy. Am J Transplant 4:169-177.
20. Vogel P, Weigler BJ, Kerr H, Hendrickx A, Barry PA. 1994. Seroepidemiologic studies of cytomegalovirus infection in a breeding population of rhesus macaques. Lab Anim Sci 44:25-30.
21. Weller TH. 1971. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations (first of two parts). N Engl J Med 285:203-214.
22. Weller TH. 1971. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations (second of two parts). N Engl J Med 285:267-274.
23. Yue Y, Kaur A, Eberhardt MK, Kassis N, Zhou SS, Tarantal AF, Barry PA. 2007. Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin 10 in rhesus macaques. J Virol 81:1095-1109.
24. Zhu J, Nieto FJ, Horne BD, Anderson JL, Muhlestein JB, Epstein SE. 2001. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation 103:45-51.
25. Zhu J, Quyyumi AA, Norman JE, Csako G, Waclawiw MA, Shearer GM, Epstein SE. 2000. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol 85:140-146.